Cyclacel Limited

Cancer Research Technology Limited

Univerzita Palackeho V Olomouci

Cyclacel Limted

Univerzita Karlova Praha

Peter Martin Fischer

Shudong Wang

Gavin Wood

Christopher Meades

Campbell McInnes

Paul Workman

Florence Irene Raynaud

Bernard Paul Nutley

Nikolai Zhelev

Stuart Wilson

Edward McDonald

Michael Jarman

Daniella I Zheleva

Janice O'Boyle

Andrew Osnowski

Miroslav Strnad

Nicholas James Westwood

Vladimir Krystof

Jan Sarek

Mark Thomas

David Blake

Janice McLachlan

Kenneth Duncan

Rene Lenobel

Iveta Frysova

Piers Collier

John R Ferguson

Paul M Blaney

Jonathan D Hull

Gail E Atkinson

Weng C Chan

Martin J I Andrews

Neil McIntyre

Ted McDonald

Mike Jarman

Alex Perry

Darren Gibson

Jan Slouka

Petr Cankar

Edward Mcdonald

Kenneth W Duncan

Janice C Mclachlan

Campbell Mcinnes

The present invention relates to compounds of formula 1  A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

Purine derivatives

A series of mono- and binuclear 4-arylazo-3,5-diamino-pyrazoles which are useful for inhibition of cyclin-dependent kinases (preferably CDK9). Hence they can be used as antimitotic-, pro-apoptotic and antiinflammatory drugs, in particular, in chemotherapy of cancer and asthma, therapy of psoriasis and parasitoses as those caused by fungi or protists, treatment of Alzheimer's disease or as antineurodegenerative drugs, or to suppress immunostimulation. These compounds are useful in a variety of utilities, including as intermediates in the preparation of flame-retardants, diagnostic reagents and therapeutics, including antivirals and immunosuppressors.

4-arylazo-3,5-diamino-pyrazole compounds and use thereof

The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof, wherein Rand Rare each independently H, C(OR) or a hydrocarbyl group optionally substituted by one or more Rgroups; Further aspects of the invention relate to pharmaceutical compositions comprising such compounds, and their use in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a CNS disorder, a stroke, alopecia and diabetes.

Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy

The present invention relates to substituted pyrimidines of formula I, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders and/or viral disorders. 

Pyrimidine compounds

The present invention relates to compounds of formula I or a pharmaceutically acceptable salt thereof wherein In a further aspect, the invention relates to pharmaceutical compositions comprising said compounds, and the use thereof in treating antiproliferative disorders and or viral disorders.

2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders

The present invention relates to compounds of formula 1 or pharmaceutically acceptable salts thereof, wherein A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, stroke, alopecia, CNS disorders, neurodegenerative disorders, or diabetes.

A compound of formula 1, or a pharmaceutically acceptable salt thereof, wherein: X is S, O, or NH; 'a' is a single bond; or 'a' is a double bond and one of Rand R, and one of Rand Rare absent; Ris H; or is selected from an alkyl group, a cycloalkyl group, a heteroaryl group, an aralkyl group, CO-alkyl, SO-alkyl, CORand an aryl group, each of which optionally contains one or more heteroatoms, and is optionally substituted with one or more groups selected from Rand R; Ris H, R, or an alkyl group optionally substituted with one or more Rgroups; R, R, R, and Rare each independently selected from H, R, an alkyl group and an alkenyl group, wherein said alkyl and alkenyl groups are optionally substituted with one or more Rgroups; or Rand R, and/or Rand Rtogether represent &#x2550;O; Ris H, R, NH(CH)R, CO(CH)R, NHCO(CH)R, O(CH)R, or an alkyl or phenyl group, each of which is optionally substituted with one or more groups selected from Rand R; Ris OR, NRR, halogen, CF, NO, COR, CN, COOR, CONRR, SORor SONRR; Ris a saturated or unsaturated 5- or 6-membered cyclic group optionally containing one or more heteroatoms selected from N, O and S, and optionally substituted with one or more Rgroups; R, R, Rand Rare each independently H or a hydrocarbyl group; and n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising compounds of formula 1, and the therapeutic use thereof in the treatment of proliferative disorders, viral disorders, CNS disorders, diabetes, stroke and cardiovascular disorders.

Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases

The present invention relates to compounds of formula I or pharmaceutically acceptable salts thereof, wherein A further aspect of the invention relates to pharmaceutical compositions comprising compounds of formula 1, and the use of said compounds in treating proliferative disorders, viral disorders, CNS disorders, diabetes, stroke, alopecia or neurodegenerative disorders.

The present invention relates to p21 derived peptides capable of inhibiting CDK/cyclin complexes, particularly cyclins A or E/CDK2, by modifying the interaction with their substrates. The peptides are derived from a C-terminal region of p21 and display selectivity for cyclin/CDK2 inhibition over cyclin/CDK4 inhibition. Variants of such peptides particularly involving certain alanine replacements are shown to be particularly potent.

p21 peptides

The present invention relates to 2-substituted 4-heteroaryl-pyrimidines, their preparation, pharmaceutical compositions containing them and their use as inhibitors of cyclin-dependent kinases (CDKs) and hence their use in the treatment of proliferative disorders such as cancer, leukaemia, psoriasis and the like.

N-(4-(4-methylthiazol-5-yl) pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds

N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-N-phenylamines as antiproliferative compounds

The present invention relates to 3&#x3b2;,28-diacetoxy-18-oxo-19,20,21,29,30-pentanorlupan-22-oic acid methanol solvate, its use in medicine and processes for its preparation.

Medicament

Inhibitors of cyclin dependent kinases as anti-cancer agent

The invention relates to modified and truncated forms of the membrane transport vector penetratin. Such truncated forms include 7-mer peptides that may in themselves include further variation.

Transport vectors

Growing community of inventors

Angus, United Kingdom

Peter Martin Fischer